Search for a doctor

Jeremy C. Jones, M.D.

  1. Hematologist / Oncologist
  2. Oncologist

Publications

  1. Siddiqui W, Pacyna JE, Phelan SM, Jones JC, Samadder NJ, Sharp RR. Factors Impacting Intent to Share Multigenic Cancer Testing Results in a Community Hospital Setting. J Pers Med. 2024 Sep 17; 14 (9) Epub 2024 Sept 17
    View PubMed
  2. Elhariri A, Patel J, Mahadevia H, Albelal D, Ahmed AK, Jones JC, Borad MJ, Babiker H. Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer. Target Oncol. 2024 Sep; 19 (5):679-689 Epub 2024 Aug 10
    View PubMed
  3. Saberzadeh-Ardestani B, Jones JC, McWilliams RR, Tougeron D, Halfdanarson TR, Guimbaud R, Hubbard JM, Flecchia C, Shi Q, Alouani E, Sonbol MB, Ticku J, Jin Z, Taieb J, Sinicrope FA. Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting. Eur J Cancer. 2024 Jan; 196:113433 Epub 2023 Nov 10
    View PubMed
  4. Elhariri A, Alhaj A, Ahn D, Sonbol MB, Bekaii-Saab T, Wu C, Rutenberg MS, Stauffer J, Starr J, Majeed U, Jones J, Borad M, Babiker H. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. World J Clin Oncol. 2023 Aug 24; 14 (8):285-296
    View PubMed
  5. Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, Garcia-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csoszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C, FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 Jul 1; 402 (10395):41-53 Epub 2023 June 15
    View PubMed
  6. Jones JC, Golafshar MA, Coston TW, Rao R, Wysokinska E, Johnson E, Esplin ED, Nussbaum RL, Heald B, Klint M, Barrus K, Uson PL Jr, Nguyen CC, Colon-Otero G, Bekaii-Saab TS, Dronca R, Kunze KL, Samadder NJ. Universal Genetic Testing vs. Guideline-Directed Testing for Hereditary Cancer Syndromes Among Traditionally Underrepresented Patients in a Community Oncology Program. Cureus. 2023 Apr; 15 (4):e37428 Epub 2023 Apr 11
    View PubMed
  7. Saberzadeh-Ardestani B, Jones JC, Hubbard JM, McWilliams RR, Halfdanarson TR, Shi Q, Sonbol MB, Ticku J, Jin Z, Sinicrope FA. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab. JAMA Netw Open. 2023 Feb 1; 6 (2):e230400 Epub 2023 Feb 01
    View PubMed
  8. Sonbol MB, Siddiqi R, Uson PLS, Pathak S, Firwana B, Botrus G, Almader-Douglas D, Ahn DH, Borad MJ, Starr J, Jones J, Stucky CC, Smoot R, Riaz IB, Bekaii-Saab T. The Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis. Oncologist. 2022 Dec 9; 27 (12):1034-1040
    View PubMed
  9. Sardar M, Recio-Boiles A, Mody K, Karime C, Chandana SR, Mahadevan D, Starr J, Jones J, Borad M, Babiker H. Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. Expert Opin Pharmacother. 2022 Dec; 23 (18):2079-2089 Epub 2022 Nov 28
    View PubMed
  10. Rutenberg MS, Hoppe BS, Starr JS, Awad Z, Thomas M, Morris CG, Johnson P, Henderson RH, Jones JC, Gharia B, Bowers S, Wolfsen HC, Krishnan S, Ko SJ, Babiker HM, Nichols RC Jr. Proton Therapy With Concurrent Chemotherapy for Thoracic Esophageal Cancer: Toxicity, Disease Control, and Survival Outcomes. Int J Part Ther. 2023 Winter; 9 (3):18-29 Epub 2022 Dec 19
    View PubMed
  11. Raoof M, Sullivan KM, Frankel PH, Fakih M, Synold TW, Lim D, Woo Y, Paz IB, Fong Y, Thomas RM, Chang S, Eng M, Tinsley R, Whelan RL, Deperalta D, Reymond MA, Jones J, Merchea A, Dellinger TH. Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design. Pleura Peritoneum. 2022 Dec; 7 (4):169-177 Epub 2022 June 21
    View PubMed
  12. Ueberroth BE, Jones JC, Bekaii-Saab TS. Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma. Pancreatology. 2022 Sep; 22 (6):741-748 Epub 2022 June 12
    View PubMed
  13. Ueberroth BE, Jones JC, Bekaii-Saab T. The role of circulating tumor DNA in evaluating minimal residual disease in luminal gastrointestinal malignancies. Clin Adv Hematol Oncol. 2022 Jul; 20 (7):444-455
    View PubMed
  14. Uson Junior PLS, Majeed U, Yin J, Botrus G, Sonbol MB, Ahn DH, Starr JS, Jones JC, Babiker H, Inabinett SR, Wylie N, Boyle AWR, Bekaii-Saab TS, Gores GJ, Smoot R, Barrett M, Nagalo B, Meurice N, Elliott N, Petit J, Zhou Y, Arora M, Dumbauld C, Barro O, Baker A, Bogenberger J, Buetow K, Mansfield A, Mody K, Borad MJ. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. JCO Precis Oncol. 2022 Jun; 6 (1):e2100274
    View PubMed
  15. Uson PLS Jr, Riegert-Johnson D, Boardman L, Kisiel J, Mountjoy L, Patel N, Lizaola-Mayo B, Borad MJ, Ahn D, Sonbol MB, Jones J, Leighton JA, Gurudu S, Singh H, Klint M, Kunze KL, Golafshar MA, Esplin ED, Nussbaum RL, Stewart AK, Bekaii-Saab TS, Jewel Samadder N. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. Clin Gastroenterol Hepatol. 2022 Mar; 20 (3):e508-e528 Epub 2021 Apr 20
    View PubMed
  16. Broccard SP, Kasbi AA, Bagaria SP, Jones J, Shoudry M, Gabriel EM. Liquid biopsies for colorectal cancer: a narrative review of ongoing clinical trials and the current use of this technology at a comprehensive cancer center. J Gastrointest Oncol. 2022 Feb; 13(1):438-449.
    View PubMed
  17. Gupta K, Jones JC, Farias VA, Mackeyev Y, Singh PK, Quiñones-Hinojosa A, Krishnan S. Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma. Front Oncol. 2022; 12:840241. Epub 2022 May 18.
    View PubMed
  18. Jones J, Ciombor K, Wu C, Bekaii-Saab T, Strickler J. Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer. Oncology (Williston Park). 2021 Oct 21; 35 (10):654-660
    View PubMed
  19. Ciombor K, Jones J, Strickler J, Bekaii-Saab T, Wu C. The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform. Oncology (Williston Park). 2021 Sep 15; 35 (9):553-559 Epub 2021 Sept 15
    View PubMed
  20. Alhaj Moustafa M, Jiang L, Kuhlman JJ, Jones J, Lou Y, Sokumbi O, Tun HW. BRAF p.V600E associated poly-neoplastic syndrome. Rare Tumors. 2021; 13:20363613211012929 Epub 2021 Apr 27
    View PubMed
  21. Wang Y, Jones JC, Jones JC, Kipp BR, Grothey A. Activity of EGFR antibody in non-V600 BRAF mutant metastatic colorectal cancer. Ann Oncol 2019 Jan 1; 30 (1):147-149
    View PubMed
  22. Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A. (Non-V600) BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol. 2017 Aug 10; 35 (23):2624-2630 Epub 2017 May 09
    View PubMed
  23. Zhang BY, Jones JC, Briggler AM, Hubbard JM, Kipp BR, Sargent DJ, Dixon JG, Grothey A. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2017 Jun; 16 (2):124-128 Epub 2016 Sept 17
    View PubMed
  24. Al-Shamsi HO, Jones J, Jones J, Fahmawi Y, Dahbour I, Tabash A, Abdel-Wahab R, Abousamra AO, Shaw KR, Xiao L, Hassan MM, Kipp BR, Kopetz S, Soliman AS, McWilliams RR, Wolff RA. Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. J Gastrointest Oncol. 2016 Dec; 7 (6):882-902
    View PubMed
  25. Salahudeen AA, Gupta A, Jones JC, Cowan RW, Vusirikala M, Kwong C, Naina HV. PTHrP-Induced Refractory Malignant Hypercalcemia in a Patient With Chronic Lymphocytic Leukemia Responding to Denosumab. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15 (9):e137-40 Epub 2015 June 19
    View PubMed
  26. Jones J, Gupta A, Naina H. Primary dural lymphoma: Complete remission after treatment with radiation therapy. Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jun 22; 32 (1):80-2 Epub 2015 June 22
    View PubMed
  27. Jones JC, Chokshi S, Pistenmaa D, Naina HV. Primary cutaneous follicle center lymphoma arising adjacent to silicone breast implant. Clin Breast Cancer. 2014 Apr; 14 (2):e65-7 Epub 2013 Oct 25
    View PubMed
PST-20469881